Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AIM

AIM - AIM ImmunoTech Inc Stock Price, Fair Value and News

0.40USD0.00 (0.00%)Market Closed
Watchlist

Market Summary

USD0.400.00
Market Closed
0.00%

AIM Stock Price

View Fullscreen

AIM RSI Chart

AIM Valuation

Market Cap

19.5M

Price/Earnings (Trailing)

-0.94

Price/Sales (Trailing)

100.96

Price/Free Cashflow

-1.11

AIM Price/Sales (Trailing)

AIM Profitability

Operating Margin

-706.20%

Return on Equity

-91.92%

Return on Assets

-74.57%

Free Cashflow Yield

-89.97%

AIM Fundamentals

AIM Revenue

Revenue (TTM)

193.5K

Rev. Growth (Yr)

119.05%

Rev. Growth (Qtr)

9.52%

AIM Earnings

Earnings (TTM)

-20.8M

Earnings Growth (Yr)

-22.41%

Earnings Growth (Qtr)

-59.22%

Breaking Down AIM Revenue

Last 7 days

-5%

Last 30 days

-15.6%

Last 90 days

-15.6%

Trailing 12 Months

-33.3%

How does AIM drawdown profile look like?

AIM Financial Health

Current Ratio

4.82

Debt/Equity

0.08

Debt/Cashflow

-9.68

AIM Investor Care

Shares Dilution (1Y)

1.58%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023156.5K168.5K193.5K0
2022167.0K146.0K134.0K140.5K
2021201.5K212.5K176.5K206.0K
2020950.0K961.0K969.0K174.5K
2019870.5K882.0K893.5K905.0K
2018409.0K229.0K177.0K859.0K
2017178.3K264.5K350.8K437.0K
2016122.8K112.5K102.3K92.0K
2015558.6K345.8K239.4K133.0K
2014765.8K715.4K690.2K665.0K
20131.2M1.1M925.3K791.0K
20121.3M1.3M1.3M1.3M
2011669.3K1.2M1.7M2.3M
2010117.0K123.0K129.0K135.0K
2009000111.0K

Tracking the Latest Insider Buys and Sells of AIM ImmunoTech Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 27, 2023
equels thomas k
bought
15,000
0.443
33,861
ceo & president
Sep 29, 2023
equels thomas k
bought
10,000
0.441
22,676
ceo & president
Aug 25, 2023
equels thomas k
bought
5,500
0.669
8,222
ceo & president
Aug 24, 2023
equels thomas k
bought
10,000
0.667
14,993
ceo & president
Jul 17, 2023
equels thomas k
bought
10,000
0.59
16,950
ceo & president
Mar 10, 2023
appelrouth stewart
sold
-83,895
1.23
-68,208
-
Jan 03, 2023
equels thomas k
bought
50,000
0.31
161,291
ceo & president
Jan 03, 2023
rodino peter w iii
bought
25,000
0.31
80,646
coo, secretary, gen. counsel
Jan 03, 2023
appelrouth stewart
bought
25,000
0.31
80,646
-
Jul 18, 2022
equels thomas k
acquired
25,000
0.76
32,895
ceo & president

1–10 of 50

Which funds bought or sold AIM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 26, 2024
Virtu Financial LLC
reduced
-46.43
-6,000
7,000
-%
Feb 16, 2024
DRW Securities, LLC
reduced
-10.71
-2,002
10,998
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
55.25
3,121
9,351
-%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
unchanged
-
-1,645
47,905
-%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
14,965
14,965
-%
Feb 14, 2024
Royal Bank of Canada
reduced
-40.53
-
-
-%
Feb 14, 2024
VANGUARD GROUP INC
unchanged
-
-30,030
874,831
-%
Feb 14, 2024
BNP PARIBAS FINANCIAL MARKETS
new
-
1.00
1.00
-%

1–10 of 48

Are Funds Buying or Selling AIM?

Are funds buying AIM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AIM
No. of Funds

Unveiling AIM ImmunoTech Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 03, 2024
deutsch todd
3.5%
1,716,100
SC 13D/A
Aug 28, 2023
deutsch todd
3.5%
1,716,100
SC 13D/A
Aug 07, 2023
deutsch todd
3.5%
1,716,100
SC 13D/A
Jul 27, 2023
deutsch todd
3.5%
1,716,100
SC 13D
Feb 08, 2021
hudson bay capital management lp
0.02%
7,747
SC 13G/A
Feb 14, 2020
anson funds management lp
4.9%
434,030
SC 13G/A
Jan 31, 2020
hudson bay capital management lp
9.99%
917,198
SC 13G
Sep 30, 2019
anson funds management lp
9.9%
1,277,222
SC 13G

Recent SEC filings of AIM ImmunoTech Inc

View All Filings
Date Filed Form Type Document
Feb 21, 2024
D/A
D/A
Feb 20, 2024
D
D
Feb 20, 2024
8-K
Current Report
Feb 09, 2024
8-K
Current Report
Jan 25, 2024
8-K
Current Report
Jan 10, 2024
8-K
Current Report
Jan 10, 2024
8-K
Current Report
Jan 03, 2024
SC 13D/A
13D - Major Acquisition
Jan 03, 2024
DFAN14A
DFAN14A
Dec 29, 2023
DEFA14A
DEFA14A

Peers (Alternatives to AIM ImmunoTech Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
35.3B
6.8B
-16.59% -47.80%
-7.48
5.15
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.0B
1.8B
-23.99% -31.71%
-43.22
10.41
76.23% 61.08%
16.3B
2.4B
-4.89% -18.90%
97.14
6.73
15.42% 18.43%
13.1B
3.7B
-7.62% -26.87%
21.93
3.55
8.87% 75.42%
MID-CAP
7.5B
396.6M
-2.06% 34.31%
-14.14
18.84
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.63
60.35
54.84% -25.61%
4.0B
240.7M
-19.08% -10.99%
-13.4
16.52
-1.03% -92.09%
3.9B
270.6M
8.92% 47.81%
-16.12
14.25
440.80% -27.84%
3.8B
726.4M
-12.60% 32.37%
-62.48
5.27
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
-3.38% -9.50%
26.46
4.74
85.90% -14.05%
687.2M
983.7M
-9.17% -57.89%
-1.26
0.7
-50.36% 17.16%
201.6M
4.9M
-14.18% -58.18%
-1.22
41.23
-57.57% 50.48%
135.5M
881.7K
289.54% 381.25%
-2.86
112.79
-77.61% -13.74%
4.3M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

AIM ImmunoTech Inc News

Latest updates
Marketscreener.com25 Feb 202401:32 am

AIM ImmunoTech Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue9.5%46.0042.0049.0057.0021.0030.0033.0050.0033.0051.0072.0021.0069.0040.0045.0081561.0029.0038173238.00
Costs and Expenses49.1%8,2035,5034,3445,6126,5424,7253,1857,4963,9623,7413,7735,1833,3913,3803,3703,1383,2663,2532,9262,9013,076
  S&GA Expenses113.3%5,4392,5502,2923,5785,1702,1812,0722,6171,7992,1452,1122,5842,0851,7172,2681,4841,8461,9421,7671,6321,273
  R&D Expenses-7.4%2,7342,9532,052-4,6051,3722,4751,036-2,0061,3171,4242,2751,1021,4638981,4371,1901,096---
Interest Expenses----------1.0019.0050.0053.0051.00249322------
Net Income-59.2%-7,816-4,909-3,661-4,389-6,385-4,851-3,820-5,746-3,826-5,913-3,742-3,965-3,306-3,303-3,794-527-2,948-2,036-3,365-1,621-3,078
Net Income Margin6.5%-107.36*-114.80*-123.23*-138.40*-155.24*-124.95*-115.60*-93.33*-98.85*-79.65*-71.05*-82.34*-11.28*--------
Free Cashflow-161.9%-5,671-2,165-3,687-6,076-4,975-2,320-2,765-5,752-3,465-1,727-3,054-2,863-2,993--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-17.1%28.0034.0037.0040.0046.0051.0054.0058.0063.0067.0074.0065.0064.0050.0042.0021.0022.0014.0016.0014.0015.00
  Current Assets-21.2%23.0029.0033.0036.0041.0046.0050.0050.0038.0041.0051.0040.0040.0035.0030.0010.0013.004.006.004.005.00
    Cash Equivalents-27.4%15.0021.0023.0027.0030.0034.0029.0032.0037.0041.0049.0039.0038.0034.0028.001.0010.001.002.000.004.00
  Net PPE-6.2%0.000.000.000.000.000.000.004.006.006.006.006.007.007.007.007.007.007.008.008.008.00
  Current Liabilities63.5%5.003.002.001.003.001.001.001.001.001.001.001.001.001.001.001.004.002.002.005.005.00
  Long Term Debt-----------2.002.002.002.002.002.002.002.002.002.002.00
    LT Debt, Current-----------0.000.000.000.000.000.000.000.000.000.000.00
    LT Debt, Non Current-----------2.002.002.002.002.002.002.002.002.002.002.00
Shareholder's Equity-25.0%23.0030.0035.0038.0043.0049.0053.0057.0062.0066.0071.0061.0061.0047.0035.0013.0013.007.004.006.006.00
  Retained Earnings-2.0%-396-389-384-380-376-369-364-361-355-351-345-341-338-335-331-327-326-323-321-318-316
  Additional Paid-In Capital0.1%419419418418418418417417417416416403399381366340340329323324323
Shares Outstanding0.8%49.0048.0048.0048.0048.0048.0048.0048.0048.0048.0048.0042.0041.0030.00-------
Float------36.00---101---84.00---10.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-162.8%-5,671-2,158-3,680-6,069-4,968-2,313-2,758-5,745-3,457-1,718-3,045-2,854-2,989-1,275-3,250-2,289-2,544-2,777-1,457-2,419-2,976
  Share Based Compensation0%50.0050.0082.00162275275242248314480526440250150196204223251175178139
Cashflow From Investing-64.7%-336-204-78.003,3632507,721-346364-366-1,152523-182-9,583-3,0823,683-5,289-232472-1,098-1,518617
Cashflow From Financing4560.0%2335.00100-25.00--12530.00-4,76112,7943,04117,16010,67525,687-56811,4338704,6501812,846

AIM Income Statement

2023-09-30
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
Clinical treatment programs - US$ 46$ 21$ 137$ 85
Total Revenues462113785
Costs and Expenses:    
Production costs3030
Research and development2,7341,3727,7394,883
General and administrative5,4395,17010,2809,569
Total Costs and Expenses8,2036,54218,04914,452
Operating Loss(8,157)(6,521)(17,912)(14,367)
Loss on investments(310)(365)(201)(1,769)
Interest and other income294172811296
Gain on sale of fixed assets3916
Redeemable warrants valuation adjustment135
Gain on sale of income tax operating losses318328900749
Net Loss$ (7,816)$ (6,385)$ (16,386)$ (15,056)
Basic loss per share$ (0.16)$ (0.13)$ (0.34)$ (0.31)
Diluted loss per share$ (0.16)$ (0.13)$ (0.34)$ (0.31)
Weighted average shares outstanding basic48,635,16548,079,21048,483,80248,036,559
Weighted average shares outstanding diluted48,635,16548,079,21048,483,80248,036,559

AIM Balance Sheet

2023-09-30
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 15,264$ 27,053
Marketable investments7,1677,137
Funds receivable from New Jersey net operating loss481,676
Prepaid expenses and other current assets263455
Total current assets22,74236,321
Property and equipment, net136195
Right of use asset, net727829
Patent and trademark rights, net2,1541,941
Other assets2,1021,202
Total assets27,86140,488
Current liabilities:  
Accounts payable2,788377
Accrued expenses1,721806
Current portion of operating lease liability207178
Total current liabilities4,7161,361
Long-term liabilities:  
Operating lease liability543659
Commitments and contingencies (Notes 12 and 13)
Stockholders’ equity:  
Preferred Stock, $0.01 par value, 5,000,000 authorized shares, inclusive of the following:
Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 48,797,450 and 48,084,287 (including 133,333 and 561,104 of unvested stock awards) as of September 30, 2023 and December 31, 2022, respectively4848
Additional paid-in capital418,796418,270
Accumulated deficit(396,932)(380,546)
Total stockholders’ equity22,60238,468
Total liabilities and stockholders’ equity27,86140,488
Series A Junior Participating Preferred Stock [Member]  
Stockholders’ equity:  
Preferred Stock, $0.01 par value, 5,000,000 authorized shares, inclusive of the following:
Series B Convertible Preferred Stock [Member]  
Stockholders’ equity:  
Preferred Stock, $0.01 par value, 5,000,000 authorized shares, inclusive of the following:$ 690$ 696
AIM
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
 CEO
 WEBSITEaimimmuno.com
 EMPLOYEES22

AIM ImmunoTech Inc Frequently Asked Questions


What is the ticker symbol for AIM ImmunoTech Inc? What does AIM stand for in stocks?

AIM is the stock ticker symbol of AIM ImmunoTech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AIM ImmunoTech Inc (AIM)?

As of Thu Feb 29 2024, market cap of AIM ImmunoTech Inc is 19.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AIM stock?

You can check AIM's fair value in chart for subscribers.

What is the fair value of AIM stock?

You can check AIM's fair value in chart for subscribers. The fair value of AIM ImmunoTech Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AIM ImmunoTech Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AIM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AIM ImmunoTech Inc a good stock to buy?

The fair value guage provides a quick view whether AIM is over valued or under valued. Whether AIM ImmunoTech Inc is cheap or expensive depends on the assumptions which impact AIM ImmunoTech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AIM.

What is AIM ImmunoTech Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 29 2024, AIM's PE ratio (Price to Earnings) is -0.94 and Price to Sales (PS) ratio is 100.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AIM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AIM ImmunoTech Inc's stock?

In the past 10 years, AIM ImmunoTech Inc has provided -0.466 (multiply by 100 for percentage) rate of return.